HHS Sec four-square behind Trump in drug cost-cutting mission

3 May 2018

Talking at the World Health Care Congress on Wednesday, Health and Human Services (HHS) Secretary Alex Azar reportedly said the White House would go “much further” than budget proposals to challenge high drug prices.

While US President Donald Trump has consistently used strong language signalling his desire to lower the cost of prescription pharmaceuticals, there have so far been few significant actions taken to accomplish this goal.

The White House budget proposal includes suggestions such as permitting US states to trial bespoke coverage and financing options in the government-run Medicaid scheme, and limiting out-of-pocket costs for Medicare beneficiaries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK